Want to join the conversation?
$VRTX 2Q15 Call: Global sales of KALYDECO this quarter were $155MM, comprised of US sales of approx. $93MM and ex-US sales of approx. $62MM. The company has seen good uptake in patients with R117H mutation following approval in US in late 2014, and in children ages 2-5 with eligible mutations following US approval at the end of March 2015.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!